Landos Biopharma, Inc.

3.70 USD
-0.52 (-12.32%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Landos Biopharma, Inc. stock is down -7.5% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 November’s closed higher than October.

About Landos Biopharma, Inc.

Landos Biopharma, Inc. discovers and develops oral therapeutics for patients with autoimmune diseases. The company's lead product candidate in development include omilancor, a gut-restricted oral therapeutic candidate that targets lanthionine synthetase C-like protein 2 (LANCL2) for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and eosinophilic esophagitis.